Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.

Ex Input:
Context: It is unanimously accepted that there is an unmet need for pain medications that are both effective and safe. Unfortunately, no really novel analgesics have been approved over the past three decades. In view of both experimental and clinical evidence of a major role for nerve growth factor (NGF) in the generation and maintenance of a wide range of pain states, drug discovery efforts focusing on the development of anti-NGF agents have aroused particular interest. Several humanized anti-NGF monoclonal antibodies (mAbs) have entered clinical trials as potential analgesics. In this respect, tanezumab is at an advanced stage of clinical development while fulranumab, fasinumab and ABT-110, previously known as PG110, are in early phases of clinical development. This Current Opinion article aims at describing the rationale for targeting NGF for pain, reviewing the analgesic efficacy and safety of anti-NGF agents based on data from fully published studies, conference abstracts, and the US Food and Drug Administration (FDA) website, and discussing the possible future of these agents in managing chronic pain. Anti-NGF mAbs produced significant pain relief and functional improvement in patients with osteoarthritis of the knee and/or hip. Conversely, studies in non-specific lower back pain generated mixed results; overall, this condition appeared to be less responsive to anti-NGF agents than osteoarthritis. Finally, there was no conclusive evidence of the effectiveness of anti-NGF mAbs in some types of chronic visceral or neuropathic pain. Furthermore, these studies raised safety concerns about anti-NGF mAbs. As a class, these drugs may cause or worsen peripheral neuropathies. But the most problematic issue-which prompted the FDA to place studies of these compounds on clinical hold in 2010-was rapid joint destruction leading to joint replacement surgery. The aetiologies of these side effects have been much debated and their pathophysiology is poorly understood. After an Arthritis Advisory Committee meeting held in March 2012, pharmaceutical companies negotiated with the FDA on the conditions for restarting clinical studies. Although the FDA lifted its clinical hold, there remain many unresolved issues about the long-term efficacy and safety of anti-NGF mAbs. While acknowledging that the future of these drugs is unforeseeable, it appears that they may not be the safe and effective painkillers that have been awaited for decades. 
 Question: What is the target of tanezumab?

Ex Output:
ngf


Ex Input:
Context: A lonely old woman who longs for a child is given a seed by a good witch. When planted, the seed grows into a flower, and inside the blossom is a tiny girl the size of the old woman's thumb. The old woman names the girl Thumbelina and raises her as her own. Although Thumbelina loves her mother, she craves companionship from someone her own size. One night, Cornelius, the fairy prince, stumbles upon Thumbelina after hearing her beautiful singing. The two take a ride on Cornelius' bumblebee, and fall in love; during this ride Mrs. Toad and her son Grundel are enchanted by Thumbelina's singing. Cornelius promises to return the next day, but after he's gone, Mrs. Toad kidnaps Thumbelina from her bed and takes her away. Thumbelina awakens on Mrs. Toad's show boat. Mrs. Toad wants Thumbelina to join their troupe and marry Grundel, who is in love with her. They leave Thumbelina alone on a lily pad in order to fetch a priest, but a friendly swallow, Jacquimo (the narrator of the film), overhears Thumbelina's cries for help and frees her. Jacquimo's friends, the jitterbugs, promise to help Thumbelina get home safely while Jacquimo sets off to find Cornelius. Meanwhile, Cornelius learns of Thumbelina's kidnapping and ventures out to find her. While trying to get home, Thumbelina is ambushed by Berkeley Beetle, who scares the jitterbugs away. He is enamoured with her singing, and promises to show her the way home if she sings at his Beetle Ball first. Thumbelina agrees, but when she's received poorly at the Beetle Ball, Beetle kicks her out without helping her. Winter is approaching. Jacquimo accidentally impales his wing on a thorn and is knocked out by the cold, while Cornelius falls into a lake and is frozen in ice. Grundel, who is searching for Thumbelina, finds Beetle and discovers she is in love with Prince Cornelius and upon some convincing from Beetle, decides to find and kidnap Cornelius to lure Thumbelina to him. Grundel forces Beetle to help him as Grundel steals his wings and won't return them until Beetle has found and captured Cornelius. Thumbelina is taken in by Miss Fieldmouse, who tells her that Cornelius has died. The two visit Miss Fieldmouse's neighbor, Mr. Mole who tells them about a dead bird he found in his tunnel earlier that day. It turns out to be Jacquimo, who Thumbelina discovers to be only unconscious. Mr. Mole wishes to marry Thumbelina; heartbroken over Cornelius's death, Thumbelina accepts. Jacquimo awakens under Thumbelina's care and leaves to find Cornelius, refusing to believe that he is dead. Meanwhile, Beetle brings Cornelius's frozen body to Grundel and informs him that Thumbelina is going to marry the Mole. After the two leave to stop the wedding, the young jitterbugs thaw Cornelius's body out. At the wedding, Thumbelina realizes at the last moment that she can't marry someone she does not love and refuses to take the vows. Grundel and Beetle crash the wedding, but Thumbelina flees from them and Mr. Mole. Cornelius intercepts the crowd and confronts Grundel, the ensuing fight resulting in them both falling into an abyss. Once outside and free, Thumbelina is reunited with Jacquimo, who takes her to Cornelius' kingdom, the Vale of the Fairies. Cornelius appears, having survived the fall, the pair are reunited, and Thumbelina accepts his proposal of marriage. The two kiss, and Thumbelina is granted her own wings. With Thumbelina's mother and the fairy court in attendance, Thumbelina and Cornelius are married and depart on their honeymoon on Cornelius's bumblebee. Images shown during the credits reveal that Beetle resumed his singing career and had gotten his wings back, Ms. Fieldmouse married Mr. Mole, and Grundel also survived the fall with minor injuries and married a female toad (implying that he lost interest in Thumbelina). 
 Question: Who thaws out the prince?

Ex Output:
the young jitterbugs


Ex Input:
Context: Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, demonstrated efficacy and safety in moderate-to-severe plaque psoriasis when administered via subcutaneous injection. Self-administration by pre-filled syringe (PFS) can offer patients clinical benefits of a drug, with increased convenience. To assess efficacy, safety and usability of secukinumab administration via PFS in subjects with moderate-to-severe plaque psoriasis. Subjects in this phase 3 trial were randomized 1:1:1 to secukinumab 300 or 150mg or matching placebo. Results to week 12 are presented here. Each treatment was delivered using a PFS once weekly to week 4, and again at week 8. Co-primary endpoints were secukinumab superiority over placebo for week 12 PASI 75 (75% reduction in Psoriasis Area and Severity Index) and IGA mod 2011 (2011 modified Investigator's Global Assessment) 0/1 response rates. Secondary endpoints included PFS usability, determined by observer rating of successful, hazard-free self-injection and subject rating of acceptability by the Self-Injection Assessment Questionnaire (SIAQ). Co-primary endpoints were met, with demonstration of superiority for each secukinumab dose vs. placebo at week 12 (PASI 75: 759%, 695% and 0% for secukinumab 300mg, 150mg and placebo; IGA mod 2011 0/1: 690%, 525% and 0%, respectively; P<00001 for all comparisons vs. placebo). PFS usability was high: 100% of subjects successfully self-administered treatment at week 1, and subjects reported high SIAQ-assessed acceptability of the PFS throughout the trial. No new/unexpected safety signals were observed. Secukinumab administration by PFS was effective, with an acceptable safety profile and high usability. The PFS provides a reliable, convenient form of secukinumab administration in subjects with moderate-to-severe plaque psoriasis. 
 Question: Which molecule is targeted by a monoclonal antibody Secukinumab?

Ex Output:

interleukin-17a